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back for the medical evaluation, which was performed on average 
35 days postdischarge (interquartile range: 19–46 days). Epidemio-
logic, clinical, and laboratory features of the patients are summa-
rized in Table 1. Of the 25 children enrolled, 13 were male and 12 
female, with a median age of 7.75 years (range 0.4–15 years). A 
respiratory form of SARS-CoV-2 infections affected all of them and 
there were no cases of COVID-19-related multisystem inflamma-
tory syndrome. Regarding comorbidities, one patient is affected by 
cystic fibrosis, and one had congenital heart disease. According to 
the definitions provided by Qiu,2 7 (28%) of them were previously 
admitted for a mild COVID-19, 14 (56%) for moderate disease, and 
4 (16%) showed a severe form of COVID-19. At hospital admission, 
13 (52%) patients had a pathologic lung ultrasound (62% of them 
showed a diffuse interstitial pattern, and 38% had both subpleural 
multiple consolidations and diffuse interstitial pattern). As previ-
ously observed,3 lung ultrasound improved concomitantly with the 
patient’s clinical condition. Nevertheless, at the follow-up examina-
tion, we still observed a mild interstitial pattern in 3 patients and 
multiple subpleural consolidations in other 2 cases. One of them 
was investigated again a month later, with a complete lung ultra-
sound normalization; the other one, affected by cystic fibrosis, dis-
played findings probably related to their chronic lung disease.
All patients had a normal hemoglobin value, lymphocyte 
count, and C-reactive protein at the follow-up check, but in 5 
patients, we found persistence of altered inflammatory mark-
ers (ferritin, fibrinogen, or D-dimer). At a second examination, 6 
weeks postdischarge, all those 5 children showed normal blood 
analysis.
We investigated the presence of IgG directed toward SARS-
CoV-2 using ELISA assay (In3diagnostic Eradikit COVID-19, Turin, 
Italy, reported sensibility for IgG: 96%) in 24 on 25 patients: 20 
(83%) children had detectable levels of SARS-CoV-2-specific IgG, 4 
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Since the beginning of the novel coronavirus pandemic, children have been less frequently and severely involved than adults, 
requiring hospitalization only in 5%–10% of cases.1
During the pandemic peak in Italy, public health services were 
overwhelmed, and little is known about the follow-up of children 
that required hospital care for SARS-CoV-2 infection. In Piedmont, 
home checks of discharged children were often limited to the nasal 
swab testing, without a proper medical evaluation. For this reason, 
we organized a clinic in the Regina Margherita Children’s Hospi-
tal, in Turin, exclusively dedicated to the postdischarge follow-up of 
COVID-19 affected children. Two weeks after the discharge, we per-
formed an initial evaluation by phone, followed by an assessment in 
the ambulatory clinic. A separate entrance was provided away from 
the other patients for our COVID-19 clinic and a dedicated nurse and 
pediatrician fully equipped with all the necessary personal protective 
equipment. Blood analysis, nasal swab, lung ultrasound, and medical 
evaluation were carried out for each patient. Moreover, a by-phone 
follow-up is currently ongoing, accounting for, on average, 130 days 
from the discharge [interquartile range: 106–148 days].
Among 28 patients admitted to the pediatric COVID-depart-
ment, from March 1 to June 1, 2020, 25 (89%) accepted coming 
TABLE 1. Epidemiologic, Laboratory, and Clinical 
Features of COVID-19 Pediatric Patients at Hospital 





Epidemiologic data  
 Female patients 13
 Male patients 12
 Age, yr (SD, range) 7.75 (0.4–15)
 Family members with COVID-19 24/25
Laboratory tests (references values— 
 alteration)
 
 White blood cells—(reference values according 
to the age)—decreased
2/22 0/25
 Lymphocytes—(reference values according to 
the age)—decreased
4/22 0/25
 Platelets—(150,000–450,000/mmc)—decreased 6/22 0/25
 C-reactive protein—(<5 mg/L)—increased 3/22 0/25
 D-dimer—(<500 ng/mL)—increased 11/16 1/25
 Erythrocyte sedimentation rate—(3–
13 mm/h)—increased
8/11 2/25
 Fibrinogen—(200–400 mg/dL)—increased 5/16 1/25
 Ferritin—(12–60 (ng/mL)—increased 7/14 3/25
 Alanine aminotransferase—(8–40 UI/L)— 
 increased
3/21 0/25
 Creatinine—(reference values according to  
 the age)—increased
2/21 1/25
SARS-CoV-2 test  
 SARS-CoV-2 pcr detection on nasal swab 25/25 0/25
 SARS-CoV-2-specific IgG positivity N/A 20/24
Pathologic lung ultrasound 13/24 5/25
 Pulmonary consolidation 5 2
 Interstitial B-lines pattern 13 5
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first manifestation in 14%. Adjusted by confounding factors, those with 
GI symptoms had higher risk of pediatric intensive care unit admission. 
GI symptoms are predictive of severity in COVID-19 children admitted to 
hospitals.
Key Words: SARS-CoV-2, hospitalization, critical care, gastrointestinal 
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(17%), despite a positive nasal swab at admission, showed a negative 
serology. Furthermore, we screened the persistence of positive nasal 
swab in our cohort: 9 (36%) children were discharged (with a still 
positive nasal swab with the recommendation to home quarantine), 
while, at the follow-up, all nasal swabs were negative.
An underestimated aspect of the follow-up of COVID-
19 affected children is the fear of resulting positive again after 
one or more negative swab results. In our experience, 3 families 
(10.7%) refused to participate at the postdischarge program due to 
the anxiety about being found still positive for SARS-CoV-2 and 
to be forced to additional 14–21 days of mandatory home isola-
tion. Psychologic obstacles in the families of COVID-19 children 
are described4 and must be taken into consideration for the correct 
management of these patients.
In conclusion, a month after the discharge, all nasal swabs 
became negative, suggesting the complete clearance of the virus 
in those more severe pediatric patients who required hospitaliza-
tion. Second, lung ultrasound findings correlated with the clinical 
improvement, showing a complete normalization within 5 weeks 
from hospital discharge in the majority of patients. Eventually, 
all our patients showed a clinical and complete laboratory recov-
ery about a month after discharge, without manifestation of any 
COVID-19-related sequelae 4 months later. An extended time 
follow-up is necessary to describe better the natural history of 
COVID-19 in children in the long-term period, but the rarity of 
mid-term sequelae allows us to predict a good prognosis of SARS-
CoV-2 infection in the pediatric age.
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The novel coronavirus (SARS-CoV-2) outbreak started in China in December 2019. The rapid transmission of the infection and its 
virulence forced the World Health Organization to declare the associ-
ated disease (COVID-19) an international public health emergency.
The typical clinical picture of COVID-19 in previously healthy 
children is a mild or even asymptomatic disease, with practically 
no associated mortality. It is well known that fever and respiratory 
symptoms, such as dry cough or dyspnea, are the most frequently 
observed. However, as knowledge of COVID-19 has progressed, 
symptoms affecting any other organ or system have been described.1
Frequency of gastrointestinal (GI) symptoms, previously 
thought to be scarce, has increased with the progression of the pan-
demic. They are of special interest in the pediatric age group, especially 
after the first descriptions of a multisystemic inflammatory syndrome 
(MIS-C), resembling Kawasaki Disease, in which GI symptoms such 
as diarrhea, abdominal pain, or vomiting are prominent.2
Uncertainties about this disease are greater at the pediatric 
age. The objective of our study was to describe COVID-19 GI man-
ifestations of hospitalized pediatric patients.
METHODS
Study Design
Multicenter, descriptive, observational study conducted in 
15 hospitals in Spain, in COVID-19 pediatric patients admitted 
from March 1 to June 3, 2020.
